want to know more?
+31 (0)20 303 1970

drug discovery in the ubiquitin field

Access to well defined ubiquitinated peptides and conjugates, which could so far not be routinely produced (bio)chemically, is of paramount importance for screening assays for the identification of new drugs, as well as for fundamental research and structural studies. Find out about how our reagents enables research in the three stages of early drug discovery. 


Identify and validate your target using UbiQ Probes.

product info


Screen your compounds targeting DUBs and Ubl proteases using UbiQ Assay reagents.  

product info

lead on target

Our reagents enable you in lead on target validation and lead optimization.

product info


about our products

UbiQ develops and commercializes ubiquitinated peptides, ubiquitin-based reagents and high throughput assays, which enable and expedite drug discovery in the rapidly expanding ubiquitin field. UbiQ, founded in 2010, is a spin-out of the Netherlands Cancer Institute (NKI), Amsterdam. 

view reagents    more info

custom made reagents

With our UbiQ technologies we are able to fully synthesize site-selective ubiquitinated peptides of native conformation, using automated solid phase peptide synthesis. This enables us to synthesize any custom made peptides.